What is the best imaging test to evaluate a 35 mm liver mass incidentally identified on a non‑contrast chest CT?

Best Test for 35mm Liver Mass Found on Non-Contrast Chest CT

For a 35mm liver mass incidentally found on non-contrast chest CT, order either multiphase contrast-enhanced CT of the abdomen or MRI of the abdomen with and without IV contrast—these are equivalent first-line options for characterization 1.

Primary Recommendation

The ACR Appropriateness Criteria explicitly addresses this exact scenario (Variant 2: indeterminate >1cm liver lesion on non-contrast CT in normal liver) and designates both multiphase contrast-enhanced CT abdomen and MRI abdomen without and with IV contrast as "usually appropriate" and equivalent alternatives 1. This means you only need to order ONE of these tests, not both.

Which One to Choose?

Choose MRI if:

• Patient has no contraindications to MRI
• You want the highest diagnostic accuracy (MRI with gadolinium has 78-83% sensitivity and 100% specificity for lesion characterization) 1
• The lesion needs definitive characterization in a single study
• Patient has any concern for chronic liver disease (even subclinical)

Choose multiphase CT if:

• MRI is unavailable or contraindicated
• Faster turnaround time is needed
• Patient cannot tolerate MRI (claustrophobia, implants)
• You're simultaneously evaluating for extrahepatic disease

Key Technical Requirements

For CT:

• Must be multiphase (arterial, portal venous, and delayed phases)
• Single-phase or portal-venous-only CT is insufficient 1
• Delayed phase washout is critical for HCC diagnosis 1

For MRI:

• Must include both pre-contrast and post-contrast sequences
• Hepatobiliary-specific contrast agents (gadoxetate) improve sensitivity to 76-97% for small lesions and allow correct characterization in 87-91% of cases 1
• Diffusion-weighted imaging (DWI) should be included as it improves differentiation between benign and malignant lesions 1

Clinical Context Matters

The recommendation above assumes no known malignancy and no chronic liver disease. If either exists, the approach changes:

If patient has known extrahepatic malignancy:

• MRI becomes slightly preferred over CT (though still equivalent) 1
• Consider FDG-PET/CT as a third equivalent option 1

If patient has chronic liver disease or cirrhosis:

• MRI with hepatobiliary contrast is superior 1
• Contrast-enhanced ultrasound becomes an additional equivalent option 1

Common Pitfalls to Avoid

1. Don't order non-contrast CT or single-phase CT for follow-up—this provides no additional diagnostic value beyond what you already have 1

2. Don't reflexively order both CT and MRI—they are equivalent alternatives, and ordering both wastes resources without improving outcomes 1

3. Don't use ultrasound as the primary follow-up for a CT-detected lesion in normal liver—while US can characterize some lesions, it has limited sensitivity and specificity compared to contrast-enhanced CT/MRI 2

4. Don't skip the arterial phase on CT—dual-phase CT has only 53% sensitivity for small lesions, while triple-phase improves detection to 61-73% 1

When Biopsy Is Needed

Biopsy is generally not the next step. It's only indicated if:

• Imaging remains indeterminate after proper contrast-enhanced CT or MRI 1
• Molecular analysis is needed for treatment planning 1
• The lesion doesn't meet definitive imaging criteria for specific diagnoses 1

Image-guided biopsy carries 9-12% bleeding risk and 0.1-0.7% needle-track seeding risk for HCC 1, so exhaust non-invasive imaging first.